Floatz logo

Carfilzomib

T-cell Lymphomas

Memorial Sloan Kettering Cancer CenterSmall moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

85 Active assets in the T-cell Lymphomas cohort.

Asset / SponsorPhaseRating
Fludarabine
GC Cell Corporation
Phase 2BBB
Brentuximab Vedotin
Yale University
Phase 4BBB
cc-5013
Samsung Medical Center
Phase 2BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Memorial Sloan Kettering Cancer Center
Phase 2BB
Cyclophosphamide
GC Cell Corporation
Phase 3BB

View all 50 →

Same molecule, other indications

Carfilzomib is also rated in:

plasma cell myelomaDormant
BB
Indicative ·
67 / 100
View asset →
MRDDormant
BB
Indicative ·
64 / 100
View asset →
Stage III Adult Diffuse Large Cell LymphomaDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →